Axio Biosolutions
Cambridge
About Axio Biosolutions
Axio is a medtech R&D and Manufacturing Company focused on Advanced Surgical and wound care. Axio has the distinction to be the first company from India to get USFDA clearance for a woundcare/hemostat product. Controlling life threatening bleeding continues to be the major cause of death from traumatic injuries. Axiostat is its flagship product developed to reduce the mortality due to traumatic bleeding. A CE approved product, Axiostat is based on a patented novel 100% chitosan platform and has variants catering to Emergency & Trauma, Military, Cardio-vascular and Dental applications.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 101 – 250
- Estimated revenue: $10K – $50K
- Total funding: $21.0M
- Funding stage: Early Stage Venture
- Last round: Series B (Jul 2021)
- Website: axiobio.com
- Phone: +91 8860786067
Industries & Categories
Emergency Medicine, Health Care, Manufacturing, Medical, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/axio-biosolutions-91169 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.